Search results
Showing 76 to 90 of 176 results for pembrolizumab
This guideline covers managing colorectal (bowel) cancer in people aged 18 and over. It aims to improve quality of life and survival for adults with colorectal cancer through management of local disease and secondary tumours (metastatic disease).
Awaiting development Reference number: GID-TA11724 Expected publication date: TBC
Pembrolizumab with BCG for treating high-risk non-muscle-invasive bladder cancer [ID6271]
Awaiting development Reference number: GID-TA11300 Expected publication date: TBC
Awaiting development Reference number: GID-TA11202 Expected publication date: TBC
Awaiting development Reference number: GID-TA11751 Expected publication date: TBC
In development Reference number: GID-TA11497 Expected publication date: TBC
In development Reference number: GID-TA11813 Expected publication date: TBC
Pembrolizumab for previously treated multiple myeloma (ID1139)
Discontinued Reference number: GID-TA10193
Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma [ID1305]
Discontinued Reference number: GID-TA10244
Awaiting development Reference number: GID-TA11137 Expected publication date: TBC
V940 with pembrolizumab for adjuvant treatment of resected high-risk stage 2 to 4 melanoma [ID6674]
Awaiting development Reference number: GID-TA11881 Expected publication date: TBC
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
Discontinued Reference number: GID-TA10418
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
Discontinued Reference number: GID-TA10380
Evidence-based recommendations on dostarlimab (Jemperli) for treating advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency in adults who have had platinum-based chemotherapy.
Awaiting development Reference number: GID-TA11882 Expected publication date: TBC